1.99Open1.99Pre Close0 Volume877 Open Interest5.00Strike Price0.00Turnover256.34%IV2.59%PremiumJan 17, 2025Expiry Date1.91Intrinsic Value100Multiplier12DDays to Expiry0.08Extrinsic Value100Contract SizeAmericanOptions Type-0.7836Delta0.2025Gamma1.51Leverage Ratio-0.0169Theta-0.0013Rho-1.18Eff Leverage0.0017Vega
Revance Therapeutics Stock Discussion
Crown Laboratories and Revance Enter into Amended and Restated Merger Agreement
Crown Laboratories and Revance Therapeutics (NASDAQ: RVNC) have announced an amended merger agreement where Crown will acquire all outstanding Revance shares for $3.10 per share in cash through a tender offer. The amendment comes after several developments, including Revance's settlement with Teoxane regarding distribution agreements and revised brand guidelines, which are expect...
📊⚡️📊
No comment yet